RxDoctor Payments Data

Anthony Petracca, MD

Family Medicine · Glens Falls, NYNPI 1487636874

Payments from drug & device makers

$1,842in general payments, 2019–2025

Across 62 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$687
  • AbbVie$377
  • AstraZeneca$243
  • Novo Nordisk$195
  • Lilly USA, LLC$84
  • Axsome Therapeutics, Inc.$69
  • plus $187 from 6 others

What the payments were for

  • Food & beverage$1,842100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,842 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$195,616
Medicare patients
386
Services billed
7,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$172,199
OzempicSemaglutide128$161,173
EliquisApixaban117$100,877
FarxigaDapagliflozin Propanediol95$97,849
JardianceEmpagliflozin86$84,751
ProliaDenosumab41$71,036
RybelsusSemaglutide25$41,513
MounjaroTirzepatide36$38,669
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$35,220
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$33,344
OxycontinOxycodone Hcl11$21,959
JanuviaSitagliptin Phosphate18$21,780
TrulicityDulaglutide22$21,238
EntrestoSacubitril/Valsartan11$20,568
MyrbetriqMirabegron28$17,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$195$202,687153 claims
AstraZenecaFarxiga, Nexium$243$102,071106 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$687$80,27992 claims
AmgenProlia$46$71,03641 claims
Lilly USA, LLCMounjaro, Trulicity$84$59,90658 claims
Johnson & JohnsonXarelto$47$17,27119 claims
AbbVieSynthroid, Linzess$377$11,973141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Glens Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →